We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s failure to address an industry dispute over allegedly false drug advertisements is a key example of why the agency should start requiring preapproval of DTC advertising, a leading consumer advocate says.
The FDA is making a major change to how it reviews DTC ads to account for an upsurge in the number of ads submitted since PhRMA’s new advertising principle went into effect Jan. 1, agency officials say.
The FDA is making a major change to how it reviews DTC ads to account for an upsurge in the number of ads submitted since PhRMA's new advertising principle went into effect Jan. 1, agency officials say.
The FDA plans to study how coupons and other price incentives affect consumer perceptions of drug risks and benefits in direct-to-consumer (DTC) print ads.
A promotional mailer for a vitamin infusion made by Mayne Pharma is false and misleading because it omits important risk information, according to an FDA warning letter that asks the company to immediately stop disseminating the materials.
Procter & Gamble Pharmaceuticals (P&G) and sanofi-aventis have a filed a lawsuit in federal court accusing Roche Pharmaceuticals and GlaxoSmithKline (GSK) of engaging in false and misleading advertising for their prescription osteoporosis medication, Boniva. P&G and sanofi-aventis market a competing osteoporosis treatment, Actonel.
Voluntary codes of conduct established by industry groups to control pharmaceutical companies' marketing practices are ineffective and routinely abused by drug makers, contends the watchdog group Public Citizen, which recently released a study documenting promotional abuses at an industry convention.
Eli Lilly has entered into a plea agreement with the federal government to resolve charges that it promoted its osteoporosis drug Evista for uses not approved by the FDA.